Table 1. Study Characteristics.
| Source | Population | Intervention (dose)/comparison | |||||
|---|---|---|---|---|---|---|---|
| Sample | Age at start, mean (SD), mo | Gestational age, mean (SD), wk | Males, % | Intervention sample, No./comparison sample, No | Follow-up time | ||
| Griffin et al,13 2020 | Healthy preterm infants | 3.29 (2.25) | 32.7 (14.3) | 52.37 | 969/484 | 150 d | Nirsevimab (1 dose of 50 mg)/placebo |
| O’Brien et al,33 2015 | Healthy infants | 2.1 (1.91) | 36 | 50.49 | 1417/710 | 150 d to 3 y | Motavizumab (5 doses of 15 mg/kg)/placebo |
| Subramanian et al,34 1998 | Preterm infants with or without BPD | 6.78 (1.46) | NR | NR | (10, 10, or 22)/20 | 150 d | Palivizumab (5 doses of 3, 10, or 15 mg/kg)/placebo |
| Hammitt et al,14 2022 | Healthy late-preterm and term infants | 2.59 | NR | 48.4 | 993/497 | 150-360 d | Nirsevimab (1 dose of 50 mg [<5 kg]/100 mg [≥5 kg])/placebo |
| Blanken et al,35 2013 | Healthy preterm infants | NR | 34 | 51.05 | 214/215 | 1 y | Palivizumab (2-5 doses of 15 mg/kg)/placebo |
| Feltes et al,36 2011 | Children aged <24 mo with CHD | 8.33 (6.46) | 3.85 (2.05) | 53.04 | 623/612 | 150 d | Motavizumab (5 doses of 15 mg/kg)/palivizumab (5 doses of 15 mg/kg) |
| Carbonell-Estrany et al,37 2010 | Preterm infants with CLD | 3.99 (3.77) | 31.1 (3.1) | 54.66 | 3329/3306 | 150 d | Motavizumab (5 doses of 15 mg/kg)/palivizumab (5 doses of 15 mg/kg) |
| Feltes et al,38 2003 | Children aged ≤24 mo with CHD | 6.65 (0.2) | 38.5 (0.1) | 53.85 | 639/648 | 150 d | Palivizumab (5 doses of 15 mg/kg)/placebo |
| Impact-RSV Study Group,32 1998 | Preterm infants with BPD | 5.8 (0.17) | 29 (0.11) | 56.86 | 1002/500 | 150 d | Palivizumab (5 doses of 15 mg/kg)/placebo |
| Simões et al,39 2021 | Healthy preterm infants | 3.2 (6.9) | NR | 53.26 | (386 or 383)/385 | 150-237 d | Suptavumab (1 or 2 doses of 30 mg)/placebo |
| Scheltema et al,40 2018 | Healthy preterm infants | NR | 34 | 51.05 | 214/215 | 6 y | Palivizumab (NR)/placebo |
| Domachowske et al,41 2018 | Healthy preterm infants | 6.5 (2.64) | 33.1 (0.8) | 40.8 | (8, 31, or 33)/20 | 360 d | Nirsevimab (1 dose of 10, 25, or 50 mg)/placebo |
| Tavsu et al,42 2014 | Preterm infants and NICU children | NR | 29.55 (17.1) | 46.25 | 41/42 | 1-2 y | Palivizumab (5 doses of 15 mg/kg)/placebo |
| Fernández et al,43 2010 | Preterm infants with or without CLD | 3.7 (2.6) | 31.1 (2.7) | 54.6 | (83 or 84)/93 | 150 d | 2 Doses motavizumab +3 doses palivizumab or 2 doses palivizumab +3 doses motavizumab/5 doses motavizumab (15 mg/kg each dose) |
Abbreviations: BPD, bronchopulmonary dysplasia; CHD, congenital heart disease; CLD, chronic lung disease; NICU, neonatal intensive care unit; NR, not reported.